Related Links Educational Materials About Clinical Trials Clinical Trials Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase I Study of Continuous Infusion Gemcitabine in Patients With Advanced Metastatic Malignancies

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase I	Treatment	Closed	18 and over	Other	LGH-3000 NCI-V01-1660, NCT00020644

Trial Description

Purpose:

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Phase I trial to study the effectiveness of gemcitabine given as a continuous infusion in treating patients who have advanced metastatic cancer.

Eligibility:

• At least 18 years old
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive a 3-day continuous infusion of gemcitabine either once every 2 weeks or once a week for 3 weeks followed by a 1-week rest period. Treatment may be repeated for as long as benefit is shown.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

Advocate Lutheran General Cancer Care Center

Brian Samuels, MD, Protocol chair(Contact information may not be current)		Ph: 847-268-8200 Email: bsamuels@oncmed.net

Registry Information
Official Title		Phase I Study of Continuous Infusion Gemcitabine
Trial Start Date		2000-03-30
Registered in ClinicalTrials.gov		NCT00020644
Date Submitted to PDQ		2001-05-01
Information Last Verified		2004-04-27

Back to Top